Aberrant expression or p27(Kip1) associated with malignant transformation of the rat urinary bladder epithelium

Carcinogenesis

Volumn 21, Issue 1, 2000, Pages 117-121

  Ogawa, Kumiko ^a,b   Kimoto, Naoya ^a   Asamoto, Makoto ^a   Nakanishi, Makoto ^a   Takahashi, Satoru ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Nagoya shi Kohseiin Geriatric Hosp   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN P27; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER EPITHELIUM; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; CONTROLLED STUDY; HYPERPLASIA; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PAPILLOMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSITIONAL CELL CARCINOMA; UROLITHIASIS; UROTHELIUM;

EID: 0033964822     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.1.117     Document Type: Article

References (36)

1. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
2. Toyoshima, H. and Hunter, T. (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
3. kip1 for restriction point control of the fibroblast cell cycle. Science, 272, 877-880.
4. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55, 1206-1210.
5. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55, 1211-1214.
6. Spirin, K.S., Simpson, J.F., Takeuchi, S., Kawamata, N., Miller, C.W. and Koeffler, H.P. (1996) p27/Kip1 mutation found in breast cancer. Cancer Res., 56, 2400-2404.
7. Kip1 protein: prognostic implications in primary breast cancer. Nature Med., 3, 227-230.
8. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med., 3, 222-225.
9. 1a,b) invasive breast carcinomas. Cancer Res., 57, 1259-1263.
10. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K. and Akiyoshi, T. (1997) p27 expression and gastric carcinoma. Nature Med., 3, 593.
11. Loda, M., Cukor, B., Tam, S.W., Lavin, P., Fiorentino, M., Draetta, G.F., Jessup, J.M. and Pagano, M. (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med., 3, 231-234.
12. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58, 542-548.
13. Lalich, J.J. (1966) Experimentally induced uracil urolithiasis in rats. J. Urol., 95, 83-86.
14. Shirai, T., Ikawa, E., Fukushima, S., Masui, T. and Ito, N. (1986) Uracil-induced urolithiasis and the development of reversible papillomatosis in the urinary bladder of F344 rats. Cancer Res., 46, 2062-2067.
15. Shirai, T., Tagawa, Y., Fukushima, S., Imaida, K. and Ito, N. (1987) Strong promoting activity of reversible uracil-induced urolithiasis on urinary bladder carcinogenesis in rats initiated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res., 47, 6726-6730.
16. Shirai, T., Fukushima, S., Tagawa, Y., Okumura, M. and Ito, N. (1989) Cell proliferation induced by uracil-calculi and subsequent development of reversible papillomatosis in the rat urinary bladder. Cancer Res., 49, 378-383.
17. Fukushima, S., Tanaka, H., Asakawa, E., Kagawa, M., Yamamoto, A. and Shirai, T. (1992) Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. Cancer Res., 52, 1675-1680.
18. Shirai, T., Shibata, M.-A., Takahashi, S., Tagawa, Y., Imaida, K. and Hirose, M. (1995) Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-pretreated rats. Carcinogenesis, 16, 501-505.
19. Tatematsu, M., Fukushima, S., Aoki, T., Mera, Y., Inoue, T. and Ito, N. (1987) Patterns of epithelial proliferation revealed by continuous administration of bromodeoxyuridine during urinary bladder carcinogenesis in rat. Jpn. J. Cancer Res., 78, 879-882.
20. Lee, C.C.R., Yamamoto, S., Morimura, K., Wanibuchi, H., Nishisaka, N., Ikemoto, S., Nakatani, T., Wada, S., Kishimoto, T. and Fukushima, S. (1997) Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer, 79, 780-789.
21. Lee, C.C.R., Yamamoto, S., Wanibuchi, H., Wada, S., Sugimura, K., Kishimoto, T. and Fukushima, S. (1997) Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res., 57, 4765-4776.
22. Watanabe, T., Katsura, Y., Yoshitake, A., Masataki, H. and Mori, T. (1994) IPAP: image processor for analytical pathology. J. Toxicol. Pathol., 7, 353-361.
23. 1 cyclins. Cell, 73, 1059-1065.
24. Sdi1/CIP1/WAF1. EMBO J., 14, 555-563.
25. Morisaki, H., Fujimoto, A., Ando, A., Nagata, Y., Ikeda, K. and Nakanishi, M. (1997) Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Ckd2. Biochem. Biophys. Res. Commun., 240, 386-390.
26. Buckley, M.F., Sweeney, K.J.E., Hamilton, J.A., Sini, R.L., Manning, D.L., Nicholson, R.I., deFazio, A., Watts, C.K.W., Musgrove, E.A. and Sutherland, R.L. (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8, 2127-2133.
27. Zhang, Y.J., Jiang, W., Chen, C.J., Lee, C.S., Kahn, S.M., Santella, R.M. and Weinstein, I.B. (1993) Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 196, 1010-1016.
28. Jiang, W., Zhang, Y.-J., Kahn, S.M., Hollstein, M.C., Santella, R.M., Lu, S.-H., Harris, C.C., Montesano, R. and Weinstein, I.B. (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl Acad. Sci. USA, 90, 9026-9030.
29. Yasui, W., Akama, Y., Kuniyasu, H., Yokozaki, H., Semba, S., Shimamoto, F. and Tahara, E. (1996) Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J. Exp. Ther. Oncol., 1, 88-94.
30. Sutter, T., Doi, S., Carnevale, K.A., Arber, N. and Weinstein, I.B. (1997) Expression of cyclins D1 and E in human colon adenocarcinomas. J. Med., 28, 285-309.
31. Furihata, M., Ohtsuki, Y., Sonobe, H., Shuin, T., Yamamoto, A., Terao, N. and Kuwahara, M. (1998) Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. Br. J. Cancer, 77, 783-788.
32. Kip1 is haplo-insufficient for tumor suppression. Nature, 396, 177-180.
33. Kip1. J. Clin. Invest., 97, 1983-1988.
34. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene, 14, 2283-2289.
35. Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. Cancer Res., 58, 3448-3454.
36. Kip1 accumulation during the cell cycle. Science, 271, 1861-1864.